+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dermatological Non-Steroidal Anti-Inflammatory Drugs Market by Route Of Administration, Product Type, Distribution Channel, End User, Indication - Global Forecast to 2030- Product Image
Dermatological Non-Steroidal Anti-Inflammatory Drugs Market by Route Of Administration, Product Type, Distribution Channel, End User, Indication - Global Forecast to 2030- Product Image
Sale

Dermatological Non-Steroidal Anti-Inflammatory Drugs Market by Route Of Administration, Product Type, Distribution Channel, End User, Indication - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6081793
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Navigating the Dermatological Non-Steroidal Anti-Inflammatory Drug Landscape

The dermatological non-steroidal anti-inflammatory drug landscape is at an inflection point as evolving patient needs, technological advances, and shifting regulatory frameworks converge. Amid rising prevalence of inflammatory skin conditions and growing demand for targeted, non-systemic therapies, stakeholders are racing to refine formulations that maximize efficacy while minimizing side effects. This confluence of clinical urgency and scientific innovation has propelled topical and systemic NSAID modalities into the spotlight, offering new possibilities for patient care and market expansion.

Understanding the nuances of this market requires a holistic view that encompasses evolving product pipelines, diverse distribution pathways, and an increasingly complex global regulatory environment. Moreover, geographic variations in healthcare infrastructure and reimbursement models add further layers of complexity. By dissecting these elements, this executive summary illuminates the critical drivers shaping the sector and prepares decision-makers to capitalize on emerging opportunities.

Emerging Drivers Redefining Treatment Paradigms

Recent years have witnessed profound shifts in therapeutic approaches to inflammatory skin disorders driven by precision medicine, digital health integration, and patient-centric formulation design. Advances in biomarker identification are enabling personalized dosage regimens and refined topical delivery systems, reducing systemic exposure and improving tolerability. Concurrently, digital health platforms-ranging from teledermatology consultations to AI-enabled adherence monitoring-are redefining patient engagement and streamlining the care continuum.

In parallel, the rise of novel excipients and formulation technologies, such as nanoemulsions and microneedle patches, is transforming how drugs penetrate the stratum corneum and reach target tissues. These breakthroughs are fostering a shift away from broad-spectrum systemic therapies toward localized, controlled-release formats. Consequently, manufacturers are reallocating R&D budgets to focus on advanced topical vehicles capable of sustaining therapeutic concentrations and enhancing patient convenience. This strategic pivot is set to redefine market expectations and competitive positioning.

How 2025 US Tariff Changes Are Reshaping Market Dynamics

The imposition of new United States tariffs in 2025 has introduced significant headwinds for import-reliant segments of the dermatological NSAID market. Components sourced from key manufacturing hubs have become subject to increased duty rates, escalating production costs for both oral and topical formulations. Many companies have responded by reassessing their supply chains, with some pursuing nearshoring strategies to mitigate tariff pressures and enhance supply resilience.

Consequently, pricing dynamics are shifting as manufacturers pass on a portion of these incremental costs to end users or absorb them to maintain market share. Parallel adjustments in reimbursement schedules and contracting terms with payers are underway, creating a ripple effect across hospital and retail pharmacy channels. While these tariff changes introduce short-term cost volatility, they also catalyze strategic realignment of manufacturing footprints and sourcing partnerships, ultimately reinforcing the industry’s capacity for agile response to external shocks.

Decoding Patient Preferences Through Market Segmentation

A nuanced understanding of administration routes reveals that oral delivery continues to secure a robust foothold through capsules, liquid formulations, and tablets valued for convenience and dosing accuracy. Simultaneously, parenteral options, including both infusion and injection formats, retain critical importance in acute care settings, facilitating rapid onset of action. Topical applications spanning creams, gels, ointments, patches, and sprays are emerging as the fastest-growing segment, driven by patient preference for localized therapy and manufacturers’ investments in skin-permeation technologies.

Evaluating product typologies, injectable preparations remain indispensable in hospital environments, while oral capsules and liquids meet outpatient and home-care demands. Oral tablets, with their established safety profile and ease of manufacture, continue to command significant market share. Within topical modalities, cream formulations differentiated across high, medium, and low concentrations enable precise titration of active ingredients to match severity of dermatological conditions. Gel forms stratified by sub-one percent, one to two percent, and above two percent concentrations offer additional flexibility, balancing potency and skin tolerability.

Distribution channels are evolving in tandem, as hospital pharmacies maintain their traditional role in acute treatment initiation, while retail pharmacies drive widespread product accessibility. Rapid growth in online pharmacy platforms is reshaping patient acquisition and fostering direct-to-consumer engagement. Finally, segmenting by end user highlights the distinct needs of hospitals, clinics, and home care settings, each requiring tailored packaging formats, delivery training, and support services. This multifaceted segmentation framework underscores the importance of aligning product development and go-to-market strategies to diverse stakeholder demands.

Uncovering Growth Hotspots Across Global Regions

Regional dynamics exhibit pronounced variation in market maturity and growth potential. In the Americas, well-established healthcare infrastructure and robust reimbursement frameworks underpin sustained demand for both systemic and topical NSAIDs, with an emphasis on value-based pricing and real-world evidence to inform formulary decisions. Europe, Middle East & Africa present a mosaic of regulatory environments; Western Europe leads in adoption of advanced delivery systems, while emerging markets in the Middle East are catalyzed by rising healthcare spend and pediatric population growth. Africa, though nascent, is attracting investment in local manufacturing to reduce import dependence.

Meanwhile, Asia-Pacific stands out for rapid expansion driven by growing urbanization, rising patient awareness, and government initiatives to improve access to dermatological care. Key markets such as China, India, and Southeast Asia are witnessing strategic partnerships between global players and domestic firms to tailor formulations that address region-specific skin types and climatic conditions. Across all regions, digital health solutions and e-pharmacy channels are gaining traction, reshaping patient journeys and accelerating market penetration.

Profiling Industry Leaders Accelerating Innovation

Leading pharmaceutical innovators are charting diverse strategic paths to capture value in the dermatological NSAID space. Major players with vertically integrated supply chains are leveraging scale to optimize manufacturing costs and ensure uninterrupted product availability. These firms frequently spearhead formulation enhancements, engaging in collaborative research with academic institutions and biotech startups to refine topical delivery platforms. Mid-sized companies are carving niche positions by focusing on specialized formulations, such as high-concentration gels for severe inflammatory conditions and transdermal patches offering sustained release.

In addition, partnerships and licensing agreements are proliferating as companies seek to augment their pipelines without incurring the full cost of in-house R&D. Strategic mergers and acquisitions are also reshaping the competitive landscape, with larger entities acquiring boutique brands known for patient-friendly delivery systems or proprietary permeation enhancers. Across the board, organizations that integrate digital patient support initiatives-from adherence apps to online triage tools-are distinguishing themselves through improved clinical outcomes and stronger patient loyalty.

Strategic Imperatives for Capturing Market Opportunities

To thrive in this competitive arena, industry leaders should prioritize a portfolio approach that balances legacy formulations with next-generation delivery systems. Investment in advanced permeation technologies and nanocarrier research can yield differentiated topical products that command premium pricing and foster brand loyalty. Simultaneously, expanding direct-to-patient digital services, including telehealth consultations and adherence monitoring platforms, enhances patient engagement and drives real-world evidence generation for payers.

Moreover, companies must proactively optimize their supply chains in response to evolving tariff landscapes by diversifying manufacturing bases and forging local partnerships. Leveraging data analytics to forecast demand trends across hospitals, clinics, and home care settings will enable more precise inventory management and reduce stock-out risks. Finally, establishing robust patient support programs that address not only drug delivery education but also access and affordability concerns will solidify market position and drive long-term growth.

Robust Methodological Framework Underpinning Analysis

This analysis is underpinned by a rigorous multi-stage research methodology combining primary and secondary data sources. Initial insights were gathered through in-depth interviews with key opinion leaders, pharmacy procurement specialists, and field sales executives to contextualize clinical and commercial dynamics. Complementing these discussions, proprietary databases and peer-reviewed literature were systematically reviewed to extract quantitative and qualitative trends. Trade publications and regulatory announcements were continuously monitored to ensure the latest policy and technology developments were captured.

Quantitative data were triangulated using multiple vendor databases and public filings to validate company performance and product uptake. Regional market dynamics were analyzed through a combination of localized market reports and government-sourced healthcare expenditure data. Finally, all findings underwent a thorough validation process involving cross-functional experts to ensure accuracy, relevance, and robustness of conclusions.

Converging Trends Poised to Influence Market Trajectory

In summary, the dermatological non-steroidal anti-inflammatory drug market stands at a pivotal juncture defined by technological innovation, shifting regulatory landscapes, and changing patient expectations. As tariff-induced cost pressures and competitive dynamics intensify, manufacturers must leverage segmentation insights and regional nuances to craft targeted strategies. The convergence of digital health platforms with advanced topical delivery technologies offers a compelling pathway to enhance patient outcomes and deliver sustainable growth.

By adopting a proactive approach-investing in permeation science, optimizing supply chains, and building patient-centric digital ecosystems-stakeholders can navigate the evolving landscape with confidence. The insights presented in this executive summary provide the strategic foundation necessary to anticipate emerging trends, mitigate risks, and seize new opportunities in this dynamic market.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Route Of Administration
    • Oral
      • Capsule
      • Liquid
      • Tablet
    • Parenteral
      • Infusion
      • Injection
    • Topical
      • Cream
      • Gel
      • Ointment
      • Patch
      • Spray
  • Product Type
    • Injectable
    • Oral Capsule
    • Oral Liquid
    • Oral Tablet
    • Topical Cream
      • High Concentration
      • Low Concentration
      • Medium Concentration
    • Topical Gel
      • 1 To 2 Percent
      • < 1 Percent
      • >2 Percent
    • Topical Ointment
    • Topical Patch
    • Topical Spray
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • End User
    • Clinics
    • Home Care Settings
    • Hospitals
  • Indication
    • Dermatological Conditions
    • Musculoskeletal Disorders
    • Osteoarthritis
    • Rheumatoid Arthritis
    • Soft Tissue Injuries
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Novartis AG
  • Bayer AG
  • Pfizer Inc.
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Dermatological Non-Steroidal Anti-Inflammatory Drugs Market, by Route Of Administration
8.1. Introduction
8.2. Oral
8.2.1. Capsule
8.2.2. Liquid
8.2.3. Tablet
8.3. Parenteral
8.3.1. Infusion
8.3.2. Injection
8.4. Topical
8.4.1. Cream
8.4.2. Gel
8.4.3. Ointment
8.4.4. Patch
8.4.5. Spray
9. Dermatological Non-Steroidal Anti-Inflammatory Drugs Market, by Product Type
9.1. Introduction
9.2. Injectable
9.3. Oral Capsule
9.4. Oral Liquid
9.5. Oral Tablet
9.6. Topical Cream
9.6.1. High Concentration
9.6.2. Low Concentration
9.6.3. Medium Concentration
9.7. Topical Gel
9.7.1. 1 To 2 Percent
9.7.2. < 1 Percent
9.7.3. >2 Percent
9.8. Topical Ointment
9.9. Topical Patch
9.10. Topical Spray
10. Dermatological Non-Steroidal Anti-Inflammatory Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Dermatological Non-Steroidal Anti-Inflammatory Drugs Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Home Care Settings
11.4. Hospitals
12. Dermatological Non-Steroidal Anti-Inflammatory Drugs Market, by Indication
12.1. Introduction
12.2. Dermatological Conditions
12.3. Musculoskeletal Disorders
12.4. Osteoarthritis
12.5. Rheumatoid Arthritis
12.6. Soft Tissue Injuries
13. Americas Dermatological Non-Steroidal Anti-Inflammatory Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Dermatological Non-Steroidal Anti-Inflammatory Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Dermatological Non-Steroidal Anti-Inflammatory Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Novartis AG
16.3.2. Bayer AG
16.3.3. Pfizer Inc.
16.3.4. Johnson & Johnson
16.3.5. GlaxoSmithKline plc
16.3.6. Sanofi S.A.
16.3.7. Viatris Inc.
16.3.8. Teva Pharmaceutical Industries Ltd.
16.3.9. Sandoz International GmbH
16.3.10. Sun Pharmaceutical Industries Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET MULTI-CURRENCY
FIGURE 2. DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CREAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OINTMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SPRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL LIQUID, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HIGH CONCENTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY LOW CONCENTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MEDIUM CONCENTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY 1 TO 2 PERCENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY < 1 PERCENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY >2 PERCENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL OINTMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL PATCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL SPRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DERMATOLOGICAL CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SOFT TISSUE INJURIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 77. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 79. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 80. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 81. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 82. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2030 (USD MILLION)
TABLE 83. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2030 (USD MILLION)
TABLE 84. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 87. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 89. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 90. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 91. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 92. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2030 (USD MILLION)
TABLE 93. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2030 (USD MILLION)
TABLE 94. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 132. UNITED KINGDOM DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2030 (USD MILLION)
TABLE 134. UNITED KINGDOM DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2030 (USD MILLION)
TABLE 135. UNITED KINGDOM DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. UNITED KINGDOM DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. UNITED KINGDOM DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 138. GERMANY DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. GERMANY DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 140. GERMANY DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 141. GERMANY DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 142. GERMANY DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 143. GERMANY DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2030 (USD MILLION)
TABLE 144. GERMANY DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2030 (USD MILLION)
TABLE 145. GERMANY DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. GERMANY DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. GERMANY DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 148. FRANCE DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. FRANCE DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 150. FRANCE DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 151. FRANCE DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 152. FRANCE DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 153. FRANCE DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2030 (USD MILLION)
TABLE 154. FRANCE DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2030 (USD MILLION)
TABLE 155. FRANCE DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. FRANCE DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. FRANCE DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2030 (USD MILLION)
TABLE 165. RUSSIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. RUSSIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. RUSSIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 168. ITALY DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. ITALY DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 170. ITALY DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 171. ITALY DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 172. ITALY DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 173. ITALY DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2030 (USD MILLION)
TABLE 174. ITALY DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2030 (USD MILLION)
TABLE 175. ITALY DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. ITALY DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. ITALY DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 178. SPAIN DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. SPAIN DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 180. SPAIN DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 181. SPAIN DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 182. SPAIN DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 183. SPAIN DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2030 (USD MILLION)
TABLE 184. SPAIN DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2030 (USD MILLION)
TABLE 185. SPAIN DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. SPAIN DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. SPAIN DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2030 (USD MILLION)
TABLE 194. UNITED ARAB EMIRATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. UNITED ARAB EMIRATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. SAUDI ARABIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. SAUDI ARABIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 210. SOUTH AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 211. SOUTH AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 212. SOUTH AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 213. SOUTH AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2030 (USD MILLION)
TABLE 214. SOUTH AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2030 (USD MILLION)
TABLE 215. SOUTH AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. SOUTH AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. SOUTH AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 218. DENMARK DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. DENMARK DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 220. DENMARK DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 221. DENMARK DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 222. DENMARK DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 223. DENMARK DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2030 (USD MILLION)
TABLE 224. DENMARK DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2030 (USD MILLION)
TABLE 225. DENMARK DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. DENMARK DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. DENMARK DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. NETHERLANDS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 230. NETHERLANDS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 231. NETHERLANDS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 232. NETHERLANDS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 233. NETHERLANDS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2030 (USD MILLION)
TABLE 234. NETHERLANDS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2030 (USD MILLION)
TABLE 235. NETHERLANDS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. NETHERLANDS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. NETHERLANDS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 238. QATAR DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. QATAR DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 240. QATAR DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 241. QATAR DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 242. QATAR DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 243. QATAR DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2030 (USD MILLION)
TABLE 244. QATAR DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2030 (USD MILLION)
TABLE 245. QATAR DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 246. QATAR DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. QATAR DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 248. FINLAND DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 249. FINLAND DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 250. FINLAND DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 251. FINLAND DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 252. FINLAND DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 253. FINLAND DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2030 (USD MILLION)
TABLE 254. FINLAND DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2030 (USD MILLION)
TABLE 255. FINLAND DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Dermatological Non-Steroidal Anti-Inflammatory Drugs market report include:
  • Novartis AG
  • Bayer AG
  • Pfizer Inc.
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.

Related Topics

Related Reports

Non-steroidal Anti-inflammatory Drugs Market by Distribution Channel, Route of Administration, Drug Class, Formulation, End User - Global Forecast to 2030 - Product Image

Non-steroidal Anti-inflammatory Drugs Market by Distribution Channel, Route of Administration, Drug Class, Formulation, End User - Global Forecast to 2030

  • Report
  • 188 Pages
  • Global
From
Non-steroidal Anti-inflammatory Drugs Market Size, Share & Trends Analysis Report By Disease Indication (Arthritis, Ophthalmic Diseases), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Non-steroidal Anti-inflammatory Drugs Market Size, Share & Trends Analysis Report By Disease Indication (Arthritis, Ophthalmic Diseases), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From
Non-Steroidal Anti-inflammatory Drugs Market Report 2025 - Product Image

Non-Steroidal Anti-inflammatory Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Report and Forecast 2024-2032 - Product Image

Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Report and Forecast 2024-2032

  • Report
  • 200 Pages
  • Global
From
Non-steroidal Anti-inflammatory Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Non-steroidal Anti-inflammatory Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 101 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.